Prime Minister asked about Spinraza

During yesterday’s Questions Time, Mary Glindon MP asked the Prime Minister about access to Spinraza.

Mrs Glindon, MP for North Tyneside, has been approached by Gary Mckie, father of six-years-old Sam and member of TreatSMA Co-ordination Team. She then relayed the question to the Prime Minister.

Mrs Glindon, who chairs the All Party Parliamentary Group for Muscular Dystrophy, was also briefed about the issue by SMA advocacy groups during an event in the Houses of Parliament earlier this year.

You can watch Theresa May’s response in the video above.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more